Amgen climbs after being upgraded to 'Outperform' at Leerink
Amgen (NASDAQ:AMGN) traded higher Wednesday after the stock was upgraded from Market Perform to Outperform at Leerink Partners. Leerink also raised its price target from $267 to...
Strong Buy
or
Horizon Therapeutics News & Analysis
-
-
NASDAQ after-hours activity: Palantir, CRH PLC, Horizon Therapeutics and others show movement
NASDAQ's After Hours Indicator saw a dip on Friday, with the index settling at 14,706.21. The after-hours volume reached a substantial 95,222,525 shares, with key stocks including Palantir...
-
Horizon Therapeutics Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple...
-
Horizon Therapeutics Reports New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data showing that disrupting the recommended TEPEZZA treatment regimen by lengthening the amount of time between infusions can...
-
Biotech Stock Roundup: MRNA’s Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More
It was a busy week for the biotech sector, with quite a few important regulatory and pipeline updates.
-
Jefferies downgrades Horizon Therapeutics to 'hold' with a price target of $116.50
An analyst from Jefferies downgraded Horizon Therapeutics (NASDAQ: HZNP) from 'buy' to 'hold' with a price target of $116.50. Prior to this rating, Horizon Therapeutics had 1 buy ratings, 5...
-
Wall Street gains as investors eye upcoming economic data
By Shristi Achar A and Noel Randewich (Reuters) - Wall Street rose on Monday, with gains in 3M (NYSE:MMM) and Goldman Sachs ahead of key inflation and jobs data this week that will offer...
-
Horizon Therapeutics gains 5% as FTC pauses challenge to Amgen deal; reactions positive
Horizon Therapeutics (NASDAQ:HZNP) shares rose 5% in pre-market Monday after the U.S. Federal Trade Commission (FTC) decided to temporarily halt its ongoing lawsuit related to Amgen's...
-
Horizon Therapeutics earnings beat by $0.19, revenue topped estimates
Investing.com - Horizon Therapeutics (NASDAQ: HZNP) reported second quarter EPS of $1.20, $0.19 better than the analyst estimate of $1.01. Revenue for the quarter came in at $945M versus the...
-
Amgen raises full-year earnings and revenue outlook
Investing.com -- Shares in Amgen (NASDAQ:AMGN) rose in premarket U.S. trading on Friday after the U.S. biotech company improved its annual earnings and revenue forecast, and said it expects...
-
Horizon Therapeutics Reports Publication of Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced the publication of the long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA® (pegloticase)...
-
Horizon Therapeutics Says New Analysis of MRI Findings Shows UPLIZNA Reduced Formation of Subclinical Spinal Cord Lesions in People With NMOSD
DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced the presentation of a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA showing a...
-
Horizon Therapeutics Announces TEPEZZA Approved in Brazil for the Treatment of Active Thyroid Eye Disease
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA for the treatment of active TED. TEPEZZA is the first and...
-
Horizon Therapeutics Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA for Treatment of Active Thyroid Eye Disease
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced positive topline results from its randomized, double-masked, placebo-controlled Phase 3 clinical trial evaluating TEPEZZA for...
-
Horizon Therapeutics Reports Publication of UPLIZNA Data
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced the publication of a new analysis from the N-MOmentum clinical trial of UPLIZNA demonstrating the utility of a robust...
-
4 big deal reports: Amgen-Horizon merger on the ropes
Here is your Pro Recap of 4 head-turning deal dispatches you may have missed this week: potential block of |Horizon/Amgen transaction, merger deals at Magellan Midstream/Oneok and Urstadt...
-
Jefferies maintains Horizon Therapeutics at 'buy' with a price target of $116.50
An analyst from Jefferies maintained Horizon Therapeutics (NASDAQ: HZNP) at 'buy' with a price target of $116.50 from a prior price target of $125.00. Prior to this rating, Horizon...
-
Midday movers: Home Depot, Capital One Financial, Tesla and more
Investing.com -- Stocks were mixed at midday Tuesday as investors waited for clarity on the direction of negotiations over raising the debt ceiling, with a June 1 deadline just weeks away....
-
U.S. stocks are falling after Home Depot report, weak retail sales
Investing.com -- U.S. stocks were falling on Tuesday after retailer Home Depot gave a weaker than expected forecast and April retail sales data showed consumers are feeling crunched. At...
-
Seagen sinks on concerns of heightened antitrust scrutiny of drug industry
Shares of biotech company Seagen (NASDAQ:SGEN) declined Tuesday morning, falling by over 6%. Weakness followed a report from Bloomberg overnight that suggested the Federal Trade Commission...
-
Horizon tumbles on potential FTC lawsuit to block Amgen deal; analysts surprised
Bloomberg News reported yesterday that the U.S. Federal Trade Commission (FTC) is expected to introduce a lawsuit to block the proposed merger between Amgen (NASDAQ:AMGN) and Horizon...
-
Wells Fargo maintains Horizon Therapeutics at 'equal weight'
An analyst from Wells Fargo maintained Horizon Therapeutics (NASDAQ: HZNP) at 'equal weight' . Prior to this rating, Horizon Therapeutics had 1 buy ratings, 7 hold ratings, and 0 sell...
-
Horizon Therapeutics earnings missed by $0.37, revenue fell short of estimates
Investing.com - Horizon Therapeutics (NASDAQ: HZNP) reported first quarter EPS of $0.83, $0.37 worse than the analyst estimate of $1.20. Revenue for the quarter came in at $832.1M versus the...
-
Horizon Therapeutics to Present UPLIZNA Data in Neuromyelitis Optica Spectrum Disorder
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced that multiple UPLIZNA analyses will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, April 22-27 in...
-
Horizon Therapeutics Announces FDA Approval of Update to Indication Language for TEPEZZA to Specify its Use in TED Patients Regardless of Disease Activity or Duration
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Indications and Usage section of the TEPEZZA...
-
Horizon Therapeutics Reports Positive Topline Data from TEPEZZA Phase 4 Trial
-- 62% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis at Week 24 (≥ 2 mm) compared with 25% of patients receiving placebo --Horizon Therapeutics plc...
-
Horizon Therapeutics Announces New Analysis of MRI Findings Show UPLIZNA Reduced Formation of Asymptomatic Optic Nerve Lesions in People With NMOSD
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical...
-
Horizon Therapeutics Reports Real-World Experience Shows TEPEZZA Was Effective in Treating People With Dysthyroid Optic Neuropathy
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease (TED) patients with DON, the majority of...
-
Horizon Therapeutics Tops Q4 EPS by 12c
Horizon Therapeutics (NASDAQ:HZNP) reported Q4 EPS of $1.21, $0.12 better than the analyst estimate of $1.09. Revenue for the quarter came in at $942 million versus the consensus estimate of...
-
Horizon Therapeutics earnings beat by $0.12, revenue topped estimates
Investing.com - Horizon Therapeutics (NASDAQ: HZNP) reported first quarter EPS of $1.21, $0.12 better than the analyst estimate of $1.09. Revenue for the quarter came in at $942M versus the...
-
Horizon Therapeutics Reports New Data Suggesting UPLIZNA for Treatment of Neuromyelitis Optica Spectrum Disorder Did Not Increase Risk of COVID-19 Infection
Horizon Therapeutics plc (Nasdaq: NASDAQ:HZNP) today announced new data from two post-hoc analyses of the N-MOmentum clinical trial of UPLIZNA for the treatment of neuromyelitis optica...
-
Amgen Kicks Off 8-part Bond Sale To Fund Horizon Acquisition - Bloomberg
Amgen (NASDAQ:AMGN) Kicks Off 8-part Bond Sale To Fund Horizon Acquisition - Bloomberg
-
Soros buys Horizon Therapeutics, First Horizon, adds to Alphabet, cuts Amazon
By Daniel Shvartsman Investing.com -- George Soros's fund Soros Fund Management opened new positions in Horizon Therapeutics (NASDAQ:HZNP) and First Horizon National Corporation (NYSE:FHN),...
-
Midday movers: Horizon Therapeutics, Coupa Software, Microsoft and more
By Liz Moyer Investing.com -- Stocks are rising as investors await key inflation data and the Federal Reserve's decision on the next direction for interest rates. Here are the midday movers...
-
U.S. stocks rise as investors await inflation data and the Fed's rate decision
By Liz Moyer Investing.com -- Blue-chip stocks were rising but tech stocks wobbled as investors await inflation data and the Federal Reserve's next decision on interest rates later this...
-
Horizon Therapeutics, Microsoft, Gap rise premarket; Amgen, Rivian fall
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, December 12th. Please refresh for updates. Amgen (NASDAQ:AMGN) stock fell 3.2% after the Wall Street Journal...
-
Amgen secures $28.3 billion deal to buy Horizon Therapeutics
By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about $28.3 billion,...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
